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Abstract
Background: Despite progress in resection for colorectal liver metastases (CLM), the majority of patients experience
recurrence. We aimed to evaluate factors influencing time to recurrence (TTR), treatment and post-recurrence
survival (PRS) related to site of recurrence.
Methods: This is a retrospective population-based cohort study (1998–2012) of consecutive patients without
extrahepatic disease treated with resection for CLM in a referral centre.
Results: A total of 311 patients underwent resection for CLM. After a median follow-up of 4.2 years (range 1.2–15.2),
209 (67.4 %) patients developed recurrence, hepatic 90, extrahepatic 59 and both 60. Median TTR was 14.0 months,
and 5-year recurrence-free status was 25.7 %. Five- and 10-year overall survival (OS) was 38.8 and 22.0 %, respectively.
Median OS was 45 months. A multivariate analysis displayed synchronous disease (hazard ratio (HR) 1.50), American
Society of Anaesthesiologists (ASA) score (HR 1.40), increasing number (HR 1.24) and size of metastases (HR 1.08)
to shorten TTR (all p < 0.05). Perioperative chemotherapy (n = 59) increased overall TTR (HR 0.63) and overall
survival (OS; HR 0.55). Hepatic TTR was correlated to synchronous disease (HR 2.07), number of lesions (HR 1.20),
R1 resection (HR 2.00) and ASA score (HR 1.69), whereas extrahepatic TTR was correlated to N stage of the
primary (HR 1.79), number (HR 1.27) and size of metastases (HR 1.16). Single-site recurrence was most common
(135 of 209, 64.5 %), while 58 patients had double- and 16 triple-site relapses. Median PRS was 24.3 months.
There was a difference in median PRS (months) according to site of relapse: liver 30.5, lung 32.3, abdominal 22.0,
liver and lung 14.3, others 14.8 (p = 0.002). Repeated liver resections were performed in n = 57 patients resulting
in 40.6 months median OS and 36.8 % 5-year OS.
Conclusions: An adverse overall TTR was correlated to number and size of metastases, ASA score and synchronous
disease. Perioperative chemotherapy increased TTR and OS after surgery for CLM. Patients with solitary post-resection
relapse in the liver or lungs had the potential for longevity due to multimodal treatment.
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Background
Surgical intervention (resection or local ablation) is the
only potentially curative option for patients with colorectal
liver metastases (CLM). Due to progress in surgical tech-
nique and perioperative care during the last two decades,
perioperative morbidity (17–38 %) and mortality (1–2 %)
have declined [1–3]. Furthermore, by multimodal treat-
ment like chemotherapy, radiofrequency ablation (RFA)
and portal vein embolization, some patients have achieved
downsizing of initially unresectable CLM and might be of-
fered a potentially curative resection [4]. Perioperative
chemotherapy has also improved progression-free survival
[5] and overall survival (OS) in the adjuvant setting [6].
Following these advancements, OS has increased to 47–
58 % in several series [3, 7, 8]. Despite this, the recurrence
rates (57–77 %) and disease-free survival have remained
almost unchanged in the same period [7, 9–11]. Due to
improved surgical approach, repeated resections are more
often offered to selected patients with recurrent disease
[12, 13]. For patients beyond the range of cure, optimal
oncological therapy may yield life extension [14, 15].
A large number of reports have evaluated survival after
resection, whereas rather few studies have highlighted
the fate of patients with recurrence according to site of
relapse.
In this paper, we aimed to analyse the (1) sites of recur-
rence after liver resections for CLM, (2) factors influencing
time to recurrence (TTR) in different sites and (3)
treatment of post-resection recurrence and the impact
on survival according to site of relapse.
Methods
This is a population-based retrospective cohort study
with a consecutive series of patients with CLM treated
at Haukeland University Hospital, Norway (1998–2012).
The data were retrospectively recorded from 1998 to
2008 and prospectively from 2009 to 2012. The unit is
the only hepato-pancreato-biliary centre in the region,
which makes this a population-based cohort from this
catchment area of 0.7 million people. Clinical data were
retrieved from the patients’ medical records. All patients
were prospectively followed up until 15 March 2014. Re-
corded variables were TNM stage and site of primary
tumour, synchronous metastases (detected within 3 months
after resection of the primary colorectal tumour [16, 17]),
time between resection of primary tumour and diagnosis of
liver metastases (disease-free interval), number and size of
metastases, chemotherapy (indication, number of cycles
and response), American Society of Anaesthesiologists
(ASA) score, date of liver resection, resection margins
(R1 <1 mm [8]), complications (Clavien-Dindo classifica-
tion [18]), in-hospital mortality, time to recurrence, sites
of recurrence and death (perioperative, cancer-related and
other causes) and last date of follow-up for survivors.
Preoperative assessments
The selection criteria for surgery were a sufficient tumour-
free liver remnant (>30 %) and absence of (a) disseminated
disease as evaluated preoperatively and/or (b) non-
resectable extrahepatic metastases. Patients with pre-
operatively detected resectable extrahepatic disease and
macroscopically incomplete resection (R2) were excluded
from further analyses (Fig. 1). Preoperative investigations
included computed tomography (CT) scan of the chest
and abdomen/pelvis and tumour marker analysis (carci-
noembryonic antigen (CEA)). In cases with an inconclu-
sive CT scan, magnetic resonance imaging (MRI) of the
liver, contrast-enhanced ultrasound and/or 18fluorodeoxy-
glucose (FDG) positron emission tomography (PET)/CT
scan were performed. Each patient was finally discussed in
a multidisciplinary team setting.
Chemotherapy
Perioperative chemotherapy was given in 59 cases.
Forty-six patients were initially considered unresectable
Fig. 1 Selection of patients. Incomplete tumour eradication: liver,
n = 3 (i.e. failure of completing two-stage resection); primary rectal
tumour not resected due to progression after liver first procedure,
n = 3; minor liver resection performed despite finding of peritoneal
carcinomatosis, n = 1
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and underwent downsizing chemotherapy. Seven patients
developed CLM while on adjuvant chemotherapy after
resection for stage III colon cancer. The Response
Evaluation Criteria in Solid Tumour (RECIST) version
1.1 was applied to evaluate the efficiency of chemotherapy
[19]. The size of the metastases was measured on CT scan
by dedicated radiologists. All patients in the perioperative
group received treatment with FOLFOX regimen (fluoro-
uracil, leucovorin and oxaliplatin) with intended six cycles
before and after surgery. The indications for perioperative
chemotherapy have changed during the study period. A
total of 17 patients were enrolled in the European Organ-
isation for Research and Treatment of Cancer (EORTC)
multicentre study 40983 in the period 2001–2004 [5].
Later on, perioperative chemotherapy given as Nordic
FLOX [20] were offered to patients <76 years with Eastern
Cooperative Oncology Group (ECOG) performance status
≤1 and no previous treatment with oxaliplatin. In the
downsizing group, patients were treated with a variety of
chemotherapy regimens. First-line treatment with Nordic
FLOX or Nordic FLIRI regimen was most commonly used
[15, 20] optionally in combination with endothelial growth
factor receptor (EGFR) inhibitors (if KRAS wild type) or
angiogenesis inhibitors.
Surgical procedures
Surgical techniques included intraoperative ultrason-
ography, repeated inflow control (Pringle manoeuvre)
and transection using Ultracision, Kelly clamp, Cavitron
Ultrasonic Surgical Aspirator (CUSA) or Ultrasonic Aspir-
ator (Olympus Sonosurg™). Throughout the period, we
have intended to obtain a parenchyma sparing approach
with wedge resections whenever possible. Formal resections
(hemihepatectomies or lobectomies) were reserved for
metastases abutting the portal triad or the hepatic veins.
To increase intended complete tumour eradication, in-
traoperative RFA (StarBurst®) and portal vein ligations/
embolization with two-stage resections were performed.
Simultaneous colorectal cancer surgery was reserved for
healthy patients with colon cancer and less advanced
CLM. Further details are listed in Table 1.
Surveillance
Follow-up after surgery included CT scan of the chest,
abdomen and pelvis every 3 months for the first 2 years,
and thereafter every 6 months for the next 3 years. After
completing the 5-year follow-up, survival data were re-
trieved from the medical record and the Norwegian Na-
tional Registry. Patients that died from other causes were
also included in the analysis of OS but were censored in
the estimation of TTR according to the definition stated
by Punt et al. [21].
Statistical analysis
Variables with possible impact on TTR and OS like size
and number of metastases, resection margins, synchronous
disease and TNM stage of primary tumour were analysed
with univariate and multivariate survival methods [22]. The
exact chi-square (χ2) test was used for categorical variables,
the t test and the one-way analysis of variance for normally
distributed variables, and the Mann-Whitney U test and
the Kruskal-Wallis test for non-normally distributed con-
tinuous variables. Univariate analyses of TTR and OS were
estimated by the Kaplan-Meier method [23] and tested for
significance with the log-rank test [24]. Multivariate ana-
lyses of risks for overall, hepatic and extrahepatic TTR were
performed as Cox proportional hazards regression report-
ing hazard ratios (HR) and 95 % confidence intervals (CI)
Table 1 Clinical characteristics
Variable, statistics Estimate
Age in years, median (range) 66.1 (22.8, 91.3)
Gender males/females—ratio 169/142
Location primary tumour
Colon, n (%) 205 (65.9)
Rectum, n (%) 101 (32.5)
Combined, n (%) 5 (1.6)
Synchronous metastasesa, n (%) 157 (50.5)
Disease-free intervalb in months, median (range) 4.2 (−11, 131)
Resections, n 311
Hemihepatectomy/lobectomy, n (%) 137 (44.1)
Wedge/segment resections, n (%) 174 (55.9)
Simultaneous radio frequency ablation, n (%) 12 (3.9)
Two-stage resections with PVL, n (%) 3 (1.0)
Simultaneous colorectal cancer surgery, n (%) 18 (5.8)
R1 resections (<1 mm) 63 (20.3)
Extent of RM in millimeter, median (range) 4 (0–50)
Number of metastases, median (range) 2 (1, 12)
Metastases diameter in centimeter, median (range) 3.0 (0.2, 15.0)
Bilobar metastases, n (%) 108 (34.7)
Number of procedures/patient (1/2/3/4/5) 254/42/11/3/1
Morbidity (Clavien-Dindo score 1/2/3/4/5) 19/28/52/5/6
Outcome of chemotherapy (RECIST criteria)
Partial response, n (%) 63 (56.2)
Stable disease, n (%) 42 (37.5)
Progression, n (%) 5 (4.4)
Unknown, n (%) 2 (1.8)
Unknown Clavien-Dindo score n = 1
RM resection margin, RECIST Response Evaluation Criteria in Solid Tumour
version 1.1
aSynchronous metastases: detection of liver metastases within 3 months
after primary colorectal resection
bDisease-free interval: time between resection of the primary colorectal
tumour and detection of CLM
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[25] A p value ≤0.05 was considered significant. OS was de-
fined as time to death irrespective of cause, and TTR was
defined as the interval between resection and the detection
of relapse [21]. The analyses were performed using SPSS
Statistics version 22 (IBM Corp., Armonk, NY, USA) and
Stata 13 statistical software (StataCorp, College Station, TX,
USA). We decided to use TTR rather than disease-free sur-
vival as an outcome in assessing recurrence patterns, since
the latter has treatment-related and non-cancer-related
deaths as endpoints [21].
Ethics
The regional committee for medical and health research
ethics, western Norway approved the study, with an ex-
emption to the requirement for obtaining informed con-
sent from patients included in the retrospective part
(1998 to 2008). In the prospective part (2009 to 2012),
patients were enrolled through written consent.
Results
A total of 342 patients were resected for CLM of whom
311 were eligible for further analysis. Patient selection
and characteristics are outlined in Fig. 1 and Table 1,
respectively.
Patterns and sites of recurrence
After a median follow-up of 4.2 years (range 1.2–15.2)
209 patients (67.4 %) developed recurrence. The sites of
recurrence were distributed between hepatic (n = 90), ex-
trahepatic (n = 59) and both locations (n = 60). Further
details are outlined in Fig. 2. Median TTR was 14.0 months,
and 5-year recurrence-free status was 25.7 %. Single-site
relapse was most common (135 of 209, 64.5 %), while
58 patients had double- and 16 triple-site relapses. TTR
was associated with number and size of metastases, syn-
chronous disease, increasing ASA score and perioperative
chemotherapy in the multivariate analysis (Tables 2 and
3). Hepatic TTR correlated with synchronous CLM, ASA
score, R1 resections and number of metastases. Extrahe-
patic TTR (including hepatic/extrahepatic) corresponded
with node positive of the primary, number and size of me-
tastases. Positive margins and synchronous disease were
insignificant. The sites of recurrence were independent on
the primary tumour location (colon vs. rectum) both in
univariate and multivariate analyses.
Chemotherapy
The clinical characteristics of patients undergoing down-
sizing or perioperative chemotherapy vs. surgery alone
are described in Table 4. Forty-five patients completing
perioperative chemotherapy experienced a longer me-
dian TTR (19.1 months) compared with patients who
aborted this treatment (n = 14, 10.8 months), downsizing
chemotherapy (n = 46, 10.4 months), surgery alone (n =
199, 14.4 months) or adjuvant chemotherapy after resection
of the primary (n = 7, 4.6 months), p = 0.005. Five-year
recurrence-free status for these groups was 43.2, 30.8, 19.5,
23.7 % and none, respectively, (p = 0.005, Fig. 3). TTR was
different between patients with response, stable disease and
progression, with a 5-year recurrence-free status of 35.3,
26.0 % and none, respectively (p = 0.021). Positive margins
influenced TTR in responders to chemotherapy where
3-year recurrence-free status in R0 and R1 was 47.8
and 7.1 % and median TTR was 2.0 and 0.4 years, re-
spectively (p < 0001). This difference was not evident in
patients with stable disease. For this group, 3-year
recurrence-free status was 30.4 % in R0 whereas all pa-
tients with R1 had recurrence within 3 years. Median
TTR was 1.1 and 1.5 years, respectively (p = 0.756).
Perioperative chemotherapy correlated to an increased
overall TTR in the multivariate analysis (Tables 2 and
3). Five- and 10-year OS with perioperative chemother-
apy vs. surgery alone was 57.0 and 31.6 % vs. 37.1 and
20.0 %, respectively (p = 0.024). Median OS in the same
groups was 73 and 43 months, respectively. This find-
ing was also confirmed in a multivariate analysis (HR
0.55 [0.34, 0.89], p = 0.014). Patients completing peri-
operative regimen had an improved 5- and 10-year OS
of 62.0 and 51.6 %, respectively.
Fig. 2 Patterns of recurrence in the three most common sites in
n = 209 patients. Note: Other sites and combinations of recurrence:
cerebral only, n= 1; liver/bones, n= 2; liver/cerebral, n= 1; lungs/cerebral,
n= 2; liver/lungs/cerebral, n= 1; liver/abdominal/bones, n= 2; liver/lungs/
bones, n= 4; liver/ovary n= 1. Recurrence was not detected in n= 101
patients with a median observation time of 4.2 years. Definitions:
Abdominal locoregional recurrence involving peritoneal, lymph
node and local recurrence
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Post-recurrence survival (PRS)
Median PRS was 24.3 months and differed according to
sites of relapse; liver 30.4; lungs 33.1; abdominal 22.0;
liver and lungs 14.3; other combinations 14.8 months as
outlined in Fig. 4 (p = 0.002). Five-year PRS in these
groups was 23.9, 16.4, 8.7, 4.1 and 13.6 %, respectively.
Median PRS was related to the number of recurrence sites;
one site 28.8; two 16.8; three 13.5 months (p = 0.001).
Hepatic re-resections were performed in n = 57 cases,
whereas 9 patients had resections of emerging lung metas-
tases. The number of recurrence sites correlated with a
secondary surgical resection (p < 0.001). Of 90 patients
with sole hepatic recurrence, 48 underwent resection, 20
chemotherapy, 6 RFA and 9 patients best supportive
care. Data were not available in 7 patients. Median PRS
(months) varied between these groups; resection 50.0;
chemotherapy 15.2; RFA 19.9; best supportive care 5.3
(p < 0.001). Patients with combined recurrence in the liver
and lungs underwent resection in 5 of 28 (17.8 %) cases.
Overall survival
Three-, 5- and 10-year OS after the first hepatic resec-
tion were 58.8, 38.8 and 22.0 %, respectively. Median OS
was 45 months. During follow-up, 17 non-CLM-related
deaths were observed (other malignant disease n = 2;
cardiac disease n = 4; other liver disease n = 2; miscellan-
eous n = 9). Five-year OS after the second liver resection
was 36.8 % and median OS 40.6 months.
Discussion
Single-site hepatic and pulmonic recurrences were most
common after surgery for CLM. Positive resection mar-
gins, number of metastases and synchronous disease were
associated with hepatic recurrence, whereas number and
size of metastases and positive primary nodal status were
correlated with extrahepatic recurrence. Perioperative
chemotherapy increased TTR and OS as well. Patients
with single-organ recurrence in the lungs or liver were of-
fered re-resections and/or supplementary chemotherapy
had an extended survival.
About two thirds experienced recurrence after hepatic
resection with the liver as the most common site (43 %)
which is fairly consistent with other reports [7, 9, 10].
Positive margins were associated with hepatic TTR,
supporting previous series from de Jong et al. where R1
Table 2 Cox regression analysis of factors affecting time to overall recurrence
Overall recurrence (TTR)
Univariate Multivariate
Variable n HR 95 % CI p HR 95 % CI p
Age/10 years 311 1.11 (0.98, 1.26) 0.113 1.08 (0.94, 1.25) 0.253
Synch. mets
No 154 1.00 Reference 0.002 1.00 Reference 0.010
Yes 157 1.65 (1.25, 2.17) 1.50 (1.10, 2.04)
No. of mets 311 1.21 (1.14, 1.30) <0.001 1.24 (1.14, 1.34) <0.001
Mets diam (cm) 311 1.11 (1.04, 1.18) 0.002 1.08 (1.01, 1.16) 0.022
RM status
R0 246 1.00 Reference 0.013 1.00 Reference 0.143
R1 63 1.53 (1.11, 2.11) 1.30 (0.92, 1.84)
ASA score (1–3) 311 1.28 (1.00, 1.65) 0.054 1.40 (1.05, 1.87) 0.022
Clavien-Dindo 311 1.12 (1.01, 1.25) 0.037 1.07 (0.95, 1.20) 0.267
N-posa
No 190 1.00 Reference 0.058 1.00 Reference 0.091
Yes 109 1.32 (0.99, 1.78) 1.30 (0.96, 1.77)
Chemotherapy
None 199 1.00 Reference 0.010 1.00 Reference 0.014
Periop. 59 0.71 (0.49, 1.05) 0.63 (0.42, 0.95)
Downsiz. 46 1.31 (0.90, 1.89) 0.93 (0.62, 1.39)
Adj. colonb 7 2.98 (1.31, 6.79) 2.80 (1.21, 6.48)
Unknown N status n = 12. Unknown RM n = 2
RM resection margins, HR hazard ratio, CI confidence interval
aN-pos: positive lymph nodes of the primary tumour in colon or rectum
bAdj. colon: adjuvant chemotherapy after surgery for stage III (node positive) colon cancer
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resection was predictive for hepatic recurrence (HR
1.36) [7]. In a former publication, we also demonstrated
a correlation between R1 resections and local recurrence
[26]. In cases with synchronous disease, sole hepatic post-
resection recurrence may indicate an underestimation of
tumour advancement due to preoperatively undetected
liver lesions. A limitation in our cohort is the lack of rou-
tinely performed preoperative MRI. Several series have
shown this modality to be more accurate than CT scan
[27–30]. With the evolvement of efficient cytotoxic reg-
imens, MRI may also yield additional information in
cases of CT-verified complete response [30]. Primary
nodal status indicated a high risk for extrahepatic re-
currence. This represents most probably a more aggres-
sive clinical course with undetected systemic disease at
the time of liver surgery. A recent study by Lee et al.
detected a significant distributive variation in metastatic
pattern, concatenating a rectal primary with extrahepatic
recurrence, and a colon primary with hepatic recurrence,
respectively [31]. No such association was verified in the
present study.
The indication for perioperative chemotherapy is still
reported as controversial [32]. The EORTC intergroup
trial 40983 demonstrated an increase in progression-free
survival in patients undergoing perioperative chemotherapy
[5], especially in patients with CEA above 5.0 [33].
However, after a long-term follow-up, no significant
benefit was obtained in OS [34]. The current study ob-
served a significant improvement in overall TTR for
the perioperative chemotherapy group compared with
resection only. This finding was not significant in the
site-specific recurrence analysis (Tables 2 and 3), most
probably due to an insufficient number of patients. Data
from the EORTC trial also demonstrated a reduction in
Table 3 Cox regression analysis of factors affecting time to
hepatic and extrahepatic recurrence
Hepatic recurrence Extrahepatic recurrencea
Multivariate
Variable HR 95 % CI p HR 95 % CI p
Age/10 years 1.00 (0.81, 1.24) 0.995 1.14 (0.95, 1.37) 0.165
Synch. mets
No 1.00 Reference 0.002 1.00 Reference 0.499
Yes 2.07 (1.28, 3.33) 1.15 (0.77, 1.73)
No. of mets 1.20 (1.07, 1.35) 0.005 1.27 (1.14, 1.41) <0.001
Mets diam (cm) 0.99 (0.88, 1.10) 0.828 1.16 (1.07, 1.27) 0.001
RM status
R0 1.00 Reference 0.010 1.00 Reference 0.769
R1 2.00 (1.20, 3.31) 0.93 (0.57, 1.52)
ASA score
(1–3) 1.69 (1.08, 2.64) 0.021 1.24 (0.85, 1.81) 0.264
Clavien-Dindo 0.99 (0.83, 1.19) 0.958 1.12 (0.96, 1.30) 0.165
N-pos
No 1.00 Reference 0.652 1.00 Reference 0.007
Yes 0.90 (0.58, 1.41) 1.79 (1.16, 2.76)
Chemotherapy
None 1.00 Reference 0.143 1.00 Reference 0.036
Periop. 0.63 (0.34, 1.18) 0.64 (0.37, 1.11)
Downsiz. 1.36 (0.78, 2.39) 0.63 (0.35, 1.14)
Adj. colon 2.28 (0.54, 9.60) 3.12 (1.10, 8.84)
Unknown N status n = 12. Unknown RM n = 2
RM resection margins, HR hazard ratio, CI confidence interval
aExtrahepatic recurrence also included combined hepatic and extrahepatic
recurrence
Table 4 Clinical characteristics in n = 304 patients with no chemotherapy, perioperative and downsizing chemotherapy in
conjunction with resection for colorectal liver metastases
Variable No chemo (n = 199) Perioperative (n = 59) Downsizing (n = 46) p
No. of mets (mean/median) 2.1/1 2.4/2 3.4/3 0.001a
Mets size (cm, median) 3.5/3 2.8/2.1 4.1/3.5 0.003a
Age (year, mean/median) 65.9/66.5 63.7/65.1 62.0/63.6 0.055b
R1 (n, %) 40 (20.2) 12 (20.7) 10 (21.7) 0.973c
N-pos primary (n, %) 68 (36.0) 19 (32.8) 21 (46.7) 0.311c
Clavien-Dindo (1–5) 61 (31.3) 24 (41.4) 16 (35.6) 0.350c
ASA (1/2/3) 20/136/43 5/50/4 2/34/10 0.069c
Synch. mets (n, %) 71 (35.7) 36 (61.0) 30 (65.2) 0.001c
Gender (M/F) 104/95 36/23 26/20 0.475c
Recurrence pattern (n, A/B) 53/82 15/18 20/15 0.256c
Seven of 311 patients had progress on chemotherapy after stage III colon cancer, not included in the analysis
A hepatic recurrence, B extrahepatic recurrence
aKruskal-Wallis test
bOne-way analysis of variance
cχ2 test
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hepatic relapse following perioperative FOLFOX regimen
[35]. In our cohort, patients in the perioperative group
had more advanced clinical course like synchronous dis-
ease and increased number of metastases compared to
patients with resection only. Positive margins influenced
TTR in cases with response (p < 0.0001) as opposed to pa-
tients with stable disease (p = 0.756). In responders after
chemotherapy, tumour shrinkage may lead to remaining
therapy-resistant islets of malignant cell clusters near the
main lesion as well as an irregular surface which may cause
local recurrence in cases with narrow or positive margins
[36]. Furthermore, we detected a significantly better 5-year
OS in the chemotherapy group, with a 5-year OS of 62 %
in patients completing chemotherapy, as opposed to other
reports [37, 38]. However, our results should be interpreted
with caution due to possible selection bias and a heteroge-
neous cohort mainly retrospectively observed.
Patients in the downsizing group presented an insignifi-
cant difference in the univariate (p = 0.155) and multivariate
analysis in overall, hepatic and extrahepatic TTR compared
with the surgery alone group (Fig. 3 and Tables 2 and 3)
despite more adverse tumour load (Table 4). These results
support a previous study by Adam et al. [4]. Patients offered
resection after progression while on adjuvant chemotherapy
after stage III colon surgery demonstrated a short median
TTR of 4.6 months. Based on this finding in this small
group of patients, surgery may not be beneficial [39].
We demonstrated that PRS was correlated to the site
of recurrence. Single-organ lesions in the lungs or liver
appeared to have the best outcome. A high proportion
of repeated hepatic resections increased the PRS in pa-
tients with hepatic recurrence. Five-year OS of 36.8 % after
the second resection was comparable to the survival rates
after the first resection (5-year OS 38.8 %). A similar sur-
vival rate has been demonstrated in several other studies
[12, 13, 40]. The use of repeated liver resections varies in
the literature. Assumpcao et al. [11] and D’Angelica et al.
[9] performed a second resection in 28 and 30 % of the
cases with recurrence, respectively, whereas Mise et al.
[10] conducted metastasectomy in 85 % of isolated hepatic
or lung recurrence. Despite unresectable lesions in the
lung, nearly 3-year median survival was observed in the
present cohort. This finding may also justify the expanding
criteria for liver resection in selected patients with unre-
sectable lung metastases [41]
Conclusions
Sites of recurrence predict the outcome after surgery
for CLM. Resection margins, number of metastases
and synchronous disease were associated with hepatic
Fig. 4 Post-recurrence survival according to sites of relapse. Log-rank
test: recurrence in lung vs. liver, p = 0.586; liver vs. abdominal, p = 0.040;
liver vs. liver/lung, p = 0.010; liver vs. other combinations, p = 0.012
Fig. 3 Time to recurrence according to different chemotherapy
regimens. PO chemo compl perioperative chemotherapy completed,
Adj. chemo adjuvant chemotherapy after stage III colon cancer
(lymph node positive) with progression of liver metastases. Log-rank
test: No chemo vs. PO chemo completed, p = 0.045; No chemo vs.
downsizing chemo, p = 0.155
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recurrence, whereas N positive (primary tumour), number
and size of metastases were associated with extrahepatic
recurrence. Perioperative chemotherapy prolonged TTR
and increased OS significantly. Patients with single-organ
relapse have the potential for longevity due to multimodal
treatment with repeated resections and supplementary
chemotherapy.
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